Protagonist Therapeutics (PTGX) Competitors $56.07 +1.08 (+1.96%) Closing price 04:00 PM EasternExtended Trading$56.07 0.00 (0.00%) As of 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PTGX vs. RDY, QGEN, MRNA, ASND, VTRS, BBIO, VRNA, BPMC, ROIV, and GRFSShould you be buying Protagonist Therapeutics stock or one of its competitors? The main competitors of Protagonist Therapeutics include Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), Moderna (MRNA), Ascendis Pharma A/S (ASND), Viatris (VTRS), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry. Protagonist Therapeutics vs. Its Competitors Dr. Reddy's Laboratories Qiagen Moderna Ascendis Pharma A/S Viatris BridgeBio Pharma Verona Pharma PLC American Depositary Share Blueprint Medicines Roivant Sciences Grifols Dr. Reddy's Laboratories (NYSE:RDY) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk. Which has more volatility & risk, RDY or PTGX? Dr. Reddy's Laboratories has a beta of 0.29, meaning that its stock price is 71% less volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.33, meaning that its stock price is 133% more volatile than the S&P 500. Do analysts prefer RDY or PTGX? Dr. Reddy's Laboratories currently has a consensus price target of $16.95, suggesting a potential upside of 19.20%. Protagonist Therapeutics has a consensus price target of $67.20, suggesting a potential upside of 19.85%. Given Protagonist Therapeutics' higher probable upside, analysts clearly believe Protagonist Therapeutics is more favorable than Dr. Reddy's Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00Protagonist Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media favor RDY or PTGX? In the previous week, Dr. Reddy's Laboratories had 4 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 17 mentions for Dr. Reddy's Laboratories and 13 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.14 beat Dr. Reddy's Laboratories' score of 0.65 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation & earnings, RDY or PTGX? Dr. Reddy's Laboratories has higher revenue and earnings than Protagonist Therapeutics. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDr. Reddy's Laboratories$3.81B3.12$663M$0.6621.55Protagonist Therapeutics$434.43M8.03$275.19M$0.7080.10 Is RDY or PTGX more profitable? Protagonist Therapeutics has a net margin of 24.88% compared to Dr. Reddy's Laboratories' net margin of 16.99%. Dr. Reddy's Laboratories' return on equity of 17.25% beat Protagonist Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dr. Reddy's Laboratories16.99% 17.25% 11.63% Protagonist Therapeutics 24.88%8.12%7.41% Do insiders and institutionals hold more shares of RDY or PTGX? 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Comparatively, 4.9% of Protagonist Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryProtagonist Therapeutics beats Dr. Reddy's Laboratories on 10 of the 15 factors compared between the two stocks. Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PTGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTGX vs. The Competition Export to ExcelMetricProtagonist TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.49B$3.13B$5.68B$9.81BDividend YieldN/A2.23%4.61%4.07%P/E Ratio80.1020.7730.6825.56Price / Sales8.03370.75464.10116.64Price / Cash12.5643.0338.2159.48Price / Book5.228.608.996.13Net Income$275.19M-$54.65M$3.25B$264.89M7 Day Performance9.79%6.55%4.78%2.67%1 Month Performance1.36%9.54%6.80%3.11%1 Year Performance38.14%14.08%30.61%25.14% Protagonist Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTGXProtagonist Therapeutics2.045 of 5 stars$56.07+2.0%$67.20+19.9%+36.7%$3.49B$434.43M80.10120Positive NewsRDYDr. Reddy's Laboratories3.1144 of 5 stars$13.80-1.0%$16.95+22.9%-13.3%$11.64B$334.26B20.9027,811News CoverageAnalyst RevisionQGENQiagen3.6603 of 5 stars$50.27+0.7%$49.40-1.7%+9.4%$11.10B$1.98B126.045,765MRNAModerna4.4022 of 5 stars$27.64+0.1%$45.61+65.0%-67.6%$10.68B$3.24B-3.675,800ASNDAscendis Pharma A/S2.4195 of 5 stars$184.15+5.5%$223.67+21.5%+37.5%$10.67B$393.54M-29.321,017VTRSViatris2.23 of 5 stars$8.94+1.5%$10.40+16.3%-6.2%$10.34B$14.74B-2.8232,000Insider TradeBBIOBridgeBio Pharma4.365 of 5 stars$47.75+0.8%$61.18+28.1%+111.1%$8.99B$221.90M-13.53400Insider TradeVRNAVerona Pharma PLC American Depositary Share2.365 of 5 stars$105.47+0.3%$109.00+3.3%+285.5%$8.95B$42.28M-52.7430Positive NewsShort Interest ↓BPMCBlueprint MedicinesN/A$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640ROIVRoivant Sciences2.7462 of 5 stars$11.51+1.8%$16.50+43.4%+2.8%$7.69B$29.05M-46.04860Positive NewsGRFSGrifols3.7075 of 5 stars$10.72-0.6%$10.30-3.9%+55.4%$7.41B$7.81B9.1623,822 Related Companies and Tools Related Companies Dr. Reddy's Laboratories Alternatives Qiagen Alternatives Moderna Alternatives Ascendis Pharma A/S Alternatives Viatris Alternatives BridgeBio Pharma Alternatives Verona Pharma PLC American Depositary Share Alternatives Blueprint Medicines Alternatives Roivant Sciences Alternatives Grifols Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTGX) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access